Not available
Quote | uniQure N.V. (NASDAQ:QURE)
Last: | $3.91 |
---|---|
Change Percent: | 0.0% |
Open: | $4.01 |
Close: | $3.91 |
High: | $4.0799 |
Low: | $3.9 |
Volume: | 585,757 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | uniQure N.V. (NASDAQ:QURE)
2024-07-01 07:15:30 ET More on uniQure Seeking Alpha’s Quant Rating on uniQure Historical earnings data for uniQure Financial information for uniQure Read the full article on Seeking Alpha For further details see: Genezen to buy uniQure's g...
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR Newswire Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. ...
Message Board Posts | uniQure N.V. (NASDAQ:QURE)
Subject | By | Source | When |
---|---|---|---|
Looks pretty positive | Thoro | investorshub | 06/20/2023 7:20:20 AM |
Do we have a winner?Turn around time? | Thoro | investorshub | 06/17/2023 8:50:17 AM |
$QURE Price gaining last trade up | Panzer | investorshub | 06/16/2023 8:49:55 PM |
and the shorts continue | Panzer | investorshub | 06/16/2023 2:50:25 AM |
$QURE MomentumIts trading up | Panzer | investorshub | 06/13/2023 1:23:30 AM |
News, Short Squeeze, Breakout and More Instantly...
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR Newswire Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. ...
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global commercial supply of HEMGENIX ® and support uniQure’s pipeline progr...
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with ...